Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

174 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ImpENSA eHealthy Conversation Skills training for healthcare professionals aimed at improving micronutrient status during the first 1000 days in South Africa.
Patro-Golab B, Choi S, Lukasik J, Walsh C, Kolodziej M, Havemann-Nel L, Venter E, Sexton K, Omer S, Goddard L, Godfrey KM, Lawrence W, Koletzko B; ImpENSA Study Group. Patro-Golab B, et al. Among authors: venter e. PLOS Glob Public Health. 2024 Dec 4;4(12):e0003833. doi: 10.1371/journal.pgph.0003833. eCollection 2024. PLOS Glob Public Health. 2024. PMID: 39630684 Free PMC article.
Immunogenicity and safety of SARS-CoV-2 recombinant spike protein vaccine in South African people living with and without HIV-1 infection: A phase 2 randomised trial.
Bennett C, Hoosain Z, Koen A, Lalloo U, Louw C, Maluleke V, Patel F, Benade G, Venter EL, Galbiati S, Shinde V, Madhi SA; Study 2019nCoV-505 Investigators Group. Bennett C, et al. Among authors: venter el. J Infect. 2024 Dec;89(6):106285. doi: 10.1016/j.jinf.2024.106285. Epub 2024 Sep 27. J Infect. 2024. PMID: 39343247 Free article. Clinical Trial.
Pharmacokinetics and safety of coformulated bictegravir, emtricitabine, and tenofovir alafenamide in children aged 2 years and older with virologically suppressed HIV: a phase 2/3, open-label, single-arm study.
Rodriguez CA, Natukunda E, Strehlau R, Venter EL, Rungmaitree S, Cunningham CK, Lalloo U, Kosalaraksa P, HellstrÖm E, Liberty A, McGrath EJ, Kaur M, Leisegang R, Hindman JT, Vieira VA, Kersey K, Cotton MF, Rakhmanina N, Gaur AH. Rodriguez CA, et al. Among authors: venter el. Lancet HIV. 2024 May;11(5):e300-e308. doi: 10.1016/S2352-3018(23)00327-2. Epub 2024 Apr 12. Lancet HIV. 2024. PMID: 38621393 Clinical Trial.
Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants.
Riou C, Bhiman JN, Ganga Y, Sawry S, Ayres F, Baguma R, Balla SR, Benede N, Bernstein M, Besethi AS, Cele S, Crowther C, Dhar M, Geyer S, Gill K, Grifoni A, Hermanus T, Kaldine H, Keeton RS, Kgagudi P, Khan K, Lazarus E, Le Roux J, Lustig G, Madzivhandila M, Magugu SFJ, Makhado Z, Manamela NP, Mkhize Q, Mosala P, Motlou TP, Mutavhatsindi H, Mzindle NB, Nana A, Nesamari R, Ngomti A, Nkayi AA, Nkosi TP, Omondi MA, Panchia R, Patel F, Sette A, Singh U, van Graan S, Venter EM, Walters A, Moyo-Gwete T, Richardson SI, Garrett N, Rees H, Bekker LG, Gray G, Burgers WA, Sigal A, Moore PL, Fairlie L. Riou C, et al. Among authors: venter em. PLOS Glob Public Health. 2024 Apr 11;4(4):e0002703. doi: 10.1371/journal.pgph.0002703. eCollection 2024. PLOS Glob Public Health. 2024. PMID: 38603677 Free PMC article.
Clearance of persistent SARS-CoV-2 associates with increased neutralizing antibodies in advanced HIV disease post-ART initiation.
Karim F, Riou C, Bernstein M, Jule Z, Lustig G, van Graan S, Keeton RS, Upton JL, Ganga Y, Khan K, Reedoy K, Mazibuko M, Govender K, Thambu K, Ngcobo N, Venter E, Makhado Z, Hanekom W, von Gottberg A, Hoque M, Karim QA, Abdool Karim SS, Manickchund N, Magula N, Gosnell BI, Lessells RJ, Moore PL, Burgers WA, de Oliveira T, Moosa MS, Sigal A. Karim F, et al. Among authors: venter e. Nat Commun. 2024 Mar 15;15(1):2360. doi: 10.1038/s41467-024-46673-2. Nat Commun. 2024. PMID: 38491050 Free PMC article.
Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants.
Riou C, Bhiman JN, Ganga Y, Sawry S, Ayres F, Baguma R, Balla SR, Benede N, Bernstein M, Besethi AS, Cele S, Crowther C, Dhar M, Geyer S, Gill K, Grifoni A, Hermanus T, Kaldine H, Keeton RS, Kgagudi P, Khan K, Lazarus E, Roux JL, Lustig G, Madzivhandila M, Magugu SF, Makhado Z, Manamela NP, Mkhize Q, Mosala P, Motlou TP, Mutavhatsindi H, Mzindle NB, Nana A, Nesamari R, Ngomti A, Nkayi AA, Nkosi TP, Omondi MA, Panchia R, Patel F, Sette A, Singh U, van Graan S, Venter EM, Walters A, Moyo-Gwete T, Richardson SI, Garrett N, Rees H, Bekker LG, Gray G, Burgers WA, Sigal A, Moore PL, Fairlie L. Riou C, et al. Among authors: venter em. medRxiv [Preprint]. 2023 Nov 20:2023.11.20.23298785. doi: 10.1101/2023.11.20.23298785. medRxiv. 2023. Update in: PLOS Glob Public Health. 2024 Apr 11;4(4):e0002703. doi: 10.1371/journal.pgph.0002703 PMID: 38045321 Free PMC article. Updated. Preprint.
174 results